Indian Researchers Develop Nanopore Sensor Technology for Earlier Detection of Parkinson’s and ALS

Indian researchers have developed an unusually sensitive nanopore-based platform capable of distinguishing molecular forms of proteins associated with Parkinson’s disease and amyotrophic lateral sclerosis (ALS), opening a possible pathway towards future diagnostic tests that could detect neurodegenerative disease biomarkers at very low concentrations.

The research was led by Dr Kozhinjampara R. Mahendran of the BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) in Thiruvananthapuram, with major contributions from researchers at RGCB, the CSIR-Indian Institute of Chemical Biology in Kolkata and Constructor University in Bremen, Germany. The peer-reviewed study was published in Nature Nanotechnology on August 28, 2026 under the title A self-assembled peptide forms α-helical nanopores for ultrasensitive biomarker profiling.

The work is significant because many proteins associated with neurodegenerative diseases appear in biological fluids at extremely low concentrations and can exist in several different structural forms. Detecting not simply the presence of such a protein, but differentiating between normal, mutated and aggregated forms, remains one of the major challenges in developing early molecular diagnostics for diseases such as Parkinson’s.

Tiny Pores That Read Individual Biomolecules

At the centre of the technology are extraordinarily small channels known as nanopores. When embedded in a membrane and exposed to an electrical potential, ions flow through these pores and generate a measurable electrical current.

When a molecule enters, passes through or interacts with a nanopore, it disrupts this ionic current. The resulting electrical signal can contain information about the molecule’s size, charge, shape and how long it interacts with the pore.

This general principle has already transformed DNA sequencing. The RGCB-led researchers are attempting to extend the concept into the much more difficult field of protein and disease-biomarker sensing.

Proteins present a particularly complex challenge because they do not behave like relatively uniform strands of DNA. Many disease-associated proteins fold, unfold, aggregate or adopt multiple shapes, and some are intrinsically disordered. Two molecules made from almost the same amino-acid sequence may therefore behave very differently depending on their conformation.

The new nanopores were designed specifically to exploit those differences.

A Single Peptide Creates Two Different Nanopores

One of the most interesting features of the discovery is the simplicity of the basic building block.

The researchers used a short 40-amino-acid peptide called pPorA, derived from the bacterial porin PorACj. The peptides spontaneously assemble into groups of eight to form α-helical channels in artificial lipid membranes.

By introducing carefully selected natural and unnatural amino acids, the researchers were able to engineer the peptide assemblies so that they formed two functionally distinct pore configurations: a small-diameter nanopore and a large-diameter nanopore.

The two versions retained the same basic eight-peptide architecture but exhibited different electrical conductances and provided different molecular-sensing capabilities. The small and large pores recorded single-channel conductances of approximately 2.4 nanosiemens and 3.5 nanosiemens respectively under the experimental conditions used in the study.

This dual-diameter architecture is particularly useful because biological biomarkers vary enormously in size. Instead of trying to force every molecule through a single fixed pore, the researchers can use different pore dimensions for different classes of biomolecules.

Detecting Alpha-Synuclein Linked to Parkinson’s Disease

The larger nanopores were used to investigate alpha-synuclein, one of the most important proteins associated with Parkinson’s disease.

Alpha-synuclein is abundant in the nervous system and normally performs physiological functions associated with neurons. In Parkinson’s disease, however, abnormal forms of the protein can misfold and aggregate. These aggregates are closely associated with the characteristic pathology of the disease.

The RGCB-led team demonstrated that its large nanopores could detect several forms of alpha-synuclein and distinguish between them through their different electrical signatures.

This included normal alpha-synuclein as well as pathological variants. One of the variants examined was A30P, a mutation associated with familial early-onset Parkinson’s disease.

The researchers also tested truncated forms of the protein and demonstrated that the nanopore could discriminate between alpha-synuclein species possessing different charge characteristics and structural properties.

Especially significant was the detection of a pathogenic C-terminal deletion form of alpha-synuclein at nanomolar affinity, with the study reporting a dissociation constant of approximately 20 nanomolar.

Such sensitivity matters because disease biomarkers can exist at very low concentrations in biological fluids, particularly during the early stages of disease.

Distinguishing Different Forms in the Same Mixture

Simply detecting alpha-synuclein would not by itself solve the diagnostic problem because the protein can also exist in people without Parkinson’s disease.

A more useful sensor needs to distinguish between different molecular states of the protein.

The researchers demonstrated that the electrical characteristics of their nanopore could distinguish individual alpha-synuclein species even when different variants were present within heterogeneous mixtures. The sensing mechanism exploits differences in charge, molecular structure and interaction with the nanopore.

This is an important aspect of the work. Biological samples such as blood contain enormous numbers of proteins, and a clinically useful sensor eventually needs to identify a disease-associated molecule despite this molecular background.

RGCB said the experimental platform was able to distinguish disease-associated from non-disease-associated forms of biomarkers even when the target molecules were present at very low concentrations in complex protein mixtures.

Watching Alpha-Synuclein Aggregate in Real Time

The researchers went beyond identifying individual alpha-synuclein variants. They also used the nanopores to monitor how the protein changes as it aggregates.

Alpha-synuclein can progress from individual molecules, or monomers, into intermediate oligomers and eventually larger fibrillar structures. Some intermediate oligomeric forms are considered particularly important in neurodegenerative toxicity.

The nanopore platform was capable of following this time-dependent progression from monomers through oligomers to fibrils, with changing structural states producing distinguishable sensing behaviour. The researchers cross-checked these transitions using additional biophysical techniques, including atomic-force microscopy and other methods.

This gives the technology a potential use beyond diagnosis.

If a nanopore can monitor the appearance and disappearance of toxic protein aggregates, researchers could potentially use it to study whether experimental drugs prevent or redirect the aggregation process.

Sensor Also Detected the Effect of an Aggregation Inhibitor

The research team demonstrated this possibility experimentally by examining alpha-synuclein in the presence of epigallocatechin gallate, or EGCG, a compound known experimentally to alter amyloid-protein aggregation.

The nanopore measurements were able to resolve changes in the aggregation pathway when the compound was present.

The study therefore proposes that the nanopore architecture could eventually become useful not merely for detecting disease biomarkers but also as a drug-screening platform for molecules designed to interfere with toxic protein aggregation.

That could make the technology relevant to pharmaceutical research into Parkinson’s disease and other disorders in which abnormal protein aggregation plays an important role.

Smaller Nanopores Target ALS-Linked Peptides

The researchers used the smaller nanopore for a different class of biomarkers.

One of these involved peptides derived from superoxide dismutase 1, or SOD1, a protein strongly associated with certain forms of amyotrophic lateral sclerosis.

Mutations in SOD1 can cause the protein to misfold and aggregate, contributing to degeneration of motor neurons in some patients with inherited ALS.

The small nanopores successfully detected SOD1-related peptides and distinguished molecular features associated with them, demonstrating that varying nanopore diameter allows the same basic platform to be adapted to very different biomarker sizes.

The researchers also tested humanin, a small mitochondrial-derived peptide associated with cell survival and apoptosis, including different molecular forms of the peptide.

Together, the experiments showed that the smaller pore could detect short disease-associated peptides while the larger pore could accommodate much larger and structurally complex proteins such as alpha-synuclein.

Why Parkinson’s Disease Is Difficult to Detect Early

Parkinson’s disease usually becomes clinically apparent through symptoms such as tremor, slowed movement, muscle rigidity and problems with balance. By the time clear motor symptoms emerge, substantial neurological changes may already have occurred.

Finding reliable biomarkers that can identify disease-related molecular changes earlier is therefore a major research objective.

Alpha-synuclein has attracted particular attention because its abnormal aggregation is intimately connected with Parkinson’s pathology. The challenge is detecting disease-relevant forms with sufficient sensitivity and specificity in accessible biological samples.

The new research addresses part of this problem by showing that a programmable nanopore can distinguish different structural and pathological forms of alpha-synuclein at very low concentrations.

Potential for Detection From Blood

One of the most promising long-term possibilities is the development of a sensor capable of detecting disease-associated alpha-synuclein from blood or other biological fluids.

The Nature Nanotechnology study specifically notes that the sensitivity demonstrated by the large nanopores highlights their potential for detecting alpha-synuclein in blood, where concentrations can be low.

RGCB similarly said the technology could eventually be adapted into point-of-care diagnostic devices capable of detecting biomarkers directly from biological fluids, including blood.

Such a device could theoretically require only a small biological sample while obtaining information from electrical signals generated by biomolecules interacting with nanoscale pores.

That vision remains a future objective rather than an available diagnostic test.

Not Yet a Clinical Parkinson’s or ALS Test

The distinction is important.

The new study demonstrates an advanced molecular sensing platform under laboratory conditions. It does not report a completed clinical trial in which blood from large groups of Parkinson’s patients, ALS patients and healthy individuals was analysed and diagnostic sensitivity and specificity established.

The published experiments largely focus on the fundamental behaviour of engineered nanopores and their ability to detect purified proteins, pathological variants, peptides and aggregation states under controlled conditions.

Before the technology could become a diagnostic product, researchers would need to demonstrate reliable performance in real biological samples and subsequently validate it across sufficiently large and diverse patient populations.

They would also have to establish clinically meaningful thresholds, demonstrate reproducibility and develop an integrated device suitable for routine diagnostic use.

The scientifically accurate description is therefore that the technology could enable earlier detection of disease-associated biomarkers, rather than saying that an early Parkinson’s diagnostic test has already been created.

A Nature-Inspired Nanopore

The nanopore architecture has another unusual feature: it originated from a biological structure rather than being designed entirely from scratch by computational methods.

The pPorA peptide is derived from PorACj, a pore-forming protein associated with the bacterium Corynebacterium jeikeium. Previous work in Mahendran’s laboratory had established that short synthetic α-helical peptides based on this system could assemble into membrane-spanning channels.

RGCB had already secured intellectual-property protection for related synthetic transmembrane peptide-pore technology, with Indian Patent No. 407575 granted in September 2022.

The latest study significantly extends that foundation by demonstrating flexible dual-diameter pores capable of discriminating complex disease-related biomolecules.

Natural Self-Assembly Meets Molecular Engineering

While nature provides the basic architecture, the researchers deliberately modified the peptide chemistry to control the properties of the nanopores.

The study incorporated unnatural amino acids at strategic positions to alter pore geometry while preserving the octameric assembly.

This combination of biological inspiration and molecular engineering allowed the researchers to create channels whose diameter and electrical properties could be tuned for specific sensing applications.

RGCB has suggested that future work could combine these nature-inspired architectures with computational protein-design approaches to create even more sensitive and programmable nanopore sensors.

Possibilities Extend Beyond Parkinson’s and ALS

The underlying platform is not inherently restricted to neurological diseases.

Because the nanopore detects physical and electrical characteristics of biomolecules, researchers could potentially engineer variants to recognise proteins associated with many different diseases.

BRIC-RGCB Director Dr Beena Pillai said the work illustrates how nanotechnology and biotechnology can be combined to address the continuing challenge of early and accurate detection of neurodegenerative disorders. The institute also believes future versions of the platform could be adapted to biomarkers associated with diseases including cancer.

Further development could therefore lead to a family of nanoscale sensors rather than one disease-specific test.

Potential Role in Point-of-Care Diagnostics

A successful point-of-care version would be particularly significant because existing high-end protein-analysis systems can require expensive equipment, specialised laboratories and technically trained personnel.

Nanopore sensing converts interactions between individual molecules into electrical signals. In principle, this makes miniaturisation possible.

The ultimate aim could be a compact analytical device in which a biological sample is introduced and disease-associated proteins are identified through their characteristic nanopore electrical signatures.

Achieving that would require considerable engineering and clinical development, but the fundamental sensing work published by the RGCB-led team provides an important technological foundation.

Indian and International Collaboration

The study was conceived and supervised by Dr Kozhinjampara R. Mahendran at BRIC-RGCB. Varsha Shaji, Neethu Puthumadathil and Vedasmiritha T. S. were associated with the RGCB Membrane Biology Laboratory, while collaborators included Dr Krishnananda Chattopadhyay and Rajeev Jain of CSIR-Indian Institute of Chemical Biology, as well as Prof Ulrich Kleinekathöfer and Kalyanashis Jana of Constructor University in Germany.

The Nature Nanotechnology paper lists eight authors: Varsha Shaji, Rajeev Jain, Neethu Puthumadathil, Kalyanashis Jana, Vedasmiritha T. S., Ulrich Kleinekathöfer, Krishnananda Chattopadhyay and Kozhinjampara R. Mahendran.

The research received Indian government support, including funding associated with the Department of Biotechnology, Indian Council of Medical Research and Council of Scientific and Industrial Research. RGCB’s announcement also identified support from the Department of Science and Technology.

From Nanopore Science to Precision Diagnostics

The deeper importance of the work lies in its ability to interrogate proteins not merely according to whether they are present, but according to their molecular state.

Many diseases involve proteins that become harmful only after they mutate, misfold or assemble into particular structures. Conventional biomarker tests can struggle to distinguish these closely related forms.

The RGCB platform demonstrated that differences in molecular charge, size, conformation and aggregation could generate distinct nanopore signatures. In the Parkinson’s experiments, this allowed several alpha-synuclein forms to be distinguished and the evolution of aggregation to be followed over time.

That raises the possibility of diagnostic technologies that provide much richer molecular information than a simple positive-or-negative protein measurement.

An Important Step, With Clinical Translation Still Ahead

The publication in Nature Nanotechnology represents a significant achievement for Indian nanobiotechnology because it combines fundamental peptide engineering, single-molecule sensing and disease-biomarker research within one platform.

The researchers have demonstrated that a single peptide system can self-assemble into differently sized nanopores and that those pores can identify molecular signatures associated with Parkinson’s disease, ALS and apoptosis at very low concentrations. They have also shown that the platform can monitor pathological alpha-synuclein aggregation and detect changes produced by an aggregation-modifying compound.

The next major challenge is translation.

For now, it should be regarded as a highly promising laboratory-stage molecular sensing technology rather than an approved diagnostic test.

That distinction does not diminish the significance of the achievement. Instead, it identifies precisely why the work matters: Indian researchers have created a programmable nanoscale sensor capable of recognising some of the subtle molecular transformations at the heart of devastating neurodegenerative diseases, providing a new technological route towards earlier diagnosis and more precise study of disease progression.

---

References

Nature Nanotechnology — Shaji, V., Jain, R., Puthumadathil, N. et al., “A self-assembled peptide forms α-helical nanopores for ultrasensitive biomarker profiling,” published August 28, 2026. DOI: 10.1038/s41565-026-02265-3. Nature Nanotechnology paper

BRIC-Rajiv Gandhi Centre for Biotechnology — Research Spotlight and institutional announcement on development of nanopore sensors for neurodegenerative-disease biomarkers. BRIC-RGCB official website

United News of India — “BRIC-RGCB researchers develop novel nanopore sensors for early detection of Parkinson’s disease,” August 29, 2026. UNI report

BRIC-RGCB Office of Technology Ventures — Background on synthetic transmembrane peptide-pore technology and Indian Patent No. 407575. RGCB nanopore technology background

---